Ortho

Ortho Clinical Diagnostics Holdings Plc (“Ortho”): Notice of UK Court Scheme Directions Hearing

Retrieved on: 
Monday, January 24, 2022
Private Securities Litigation Reform Act, Youth justice in England and Wales, Attention, Companies Act 2006, U.S. Securities and Exchange Commission, Commission, SVC, Nature, Computershare, Depository Trust & Clearing Corporation, JOINT, Company, Microsoft, Failure, Telephone, TO, Intention, Practice, Proxy, Takeover, Part, Ownership, Mergers and acquisitions, Software, Trust, IR, Securities Act of 1933, Topco, THE, Hearing, England, High Court, GLOBE, Form, Sale, Communication, Security (finance), Prospectus, Terminology, Online gambling, Cryptocurrency, Risk management, Ortho, Quidel Corporation

The UK Scheme Directions Hearing is expected to take place on February 15, 2022.

Key Points: 
  • The UK Scheme Directions Hearing is expected to take place on February 15, 2022.
  • It is a matter for the UK Court as to whether the hearing is in person, virtual only using Microsoft Teams (or such other videoconferencing software as the UK Court decides) or hybrid.
  • The documents filed with the UK Court in connection with the UK Scheme Directions Hearing will be made available on Orthos website at https://ir.orthoclinicaldiagnostics.com as soon as practicable after each document is filed at the UK Court in connection with the UK Scheme Directions Hearing.
  • If any shareholders have any questions relating to UK Scheme Directions Hearing they are encouraged to make contact by emailing [email protected].

Halper Sadeh LLP Investigates FLMN, VCRA, ADTX, OCDX; Shareholders are Encouraged to Contact the Firm

Retrieved on: 
Saturday, January 15, 2022
Advertising, VCRA, Quidel Corporation, Stryker Corporation, NYSE, NASDAQ, GLOBE, Sale, Fraud, Security (finance), Ortho

If you are a Falcon shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Falcon shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options.
  • Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Halper Sadeh LLP Investigates EPAY, VRS, HXOH, OCDX, ADTX; Shareholders are Encouraged to Contact the Firm

Retrieved on: 
Tuesday, January 11, 2022
Advertising, Quidel Corporation, NYSE, NASDAQ, Thoma Bravo, American Securities, Recto and verso, OTC, Hexion, Verso Corporation, Sale, Fraud, Security (finance), Ortho

If you are a Verso shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Verso shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options.
  • Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

National Acclaim, Medical Research and Generous Donors Highlight a Remarkable Year of Achievement for Orthopaedic Institute for Children

Retrieved on: 
Tuesday, January 11, 2022
Family, Health, Consumer, Hospitals, Children, General Health, Magnet, University of California, Berkeley, Patient, Ortho, Research, Surgeon, Accreditation Association for Ambulatory Health Care, Injury, UC, U.S. News & World Report, COVID-19, Lists of schools in England, Superintendent, Foundation, Accreditation, PSAT, UCLA Health, Volunteering, Health, Actor, CT scan, Faculty, News, Recreation, Hospital, Association, USC, OIC, Child, Secondary school, Exela Technologies, UCLA, AAAHC, International Kids Fund, Medicine, Pharmaceutical industry

Once again in 2021, OIC’s faculty continued to share its deep knowledge with others, as evidenced by the publishing/co-publishing of more than 40 articles on advancements in orthopaedic care. This academic mission was also demonstrated by the launch of Educate2Elevate, a new mentorship program that pairs students from Orthopaedic Medical Magnet High School – located adjacent to OIC’s downtown LA campus -- with individual mentors (OIC volunteers) who are currently at colleges such as UCLA, USC, UC Berkeley and others. Since September, Educate2Elevate has hosted PSAT/SAT, UC Application and Financial Aid Workshops for over 50 Ortho High students and OIC patients. In 2021 the High School was named among the top 3% of public high schools in California by the Superintendent of Public Instruction.

Key Points: 
  • Prestigious national acclaim, groundbreaking medical research, training of tomorrows healthcare leaders and generous donor involvement were among the 2021 highlights of Los Angeles Orthopaedic Institute for Children.
  • Among the highlights of the year just concluded was OIC being ranked among the top pediatric orthopaedic programs in the nation by U.S. News & World Report.
  • Orthopaedic Institute for Children was founded in 1911 as Los Angeles Orthopaedic Hospital and today is the largest pediatric orthopaedic facility on the West Coast focused solely on musculoskeletal conditions in children.
  • Our locations in downtown Los Angeles, Santa Monica, Westwood and Calexico treat the full spectrum of pediatric orthopaedic disorders and injuries.

Halper Sadeh LLP Investigates CSLT, VCRA, HXOH, OCDX; Shareholders are Encouraged to Contact the Firm

Retrieved on: 
Sunday, January 9, 2022
Fraud, OTC, VCRA, American Securities, Quidel Corporation, Castlight Health, CSLT, NYSE, Hexion, Stryker Corporation, NASDAQ, Advertising, Sale, GLOBE, Security (finance), Ortho

If you are a Vocera shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Vocera shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options.
  • Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Ortho Clinical Diagnostics Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2021

Retrieved on: 
Thursday, January 6, 2022
COVID-19, Insurance, Review, Table, Organization, Intellectual property, Lists of disasters, Twitter, GAAP, Data management, Defense, Quidel Corporation, United, Webcast, Efficiency, Food and Drug Administration, High Court, Compliance, Youth justice in England and Wales, Board, Union, Board of directors, Nasdaq, Facebook, Interest, Government, Safety, Food, Securities Act of 1933, Health, Company, Ownership, Patient, Forward-looking statement, Securities Exchange Act of 1934, Mission statement, Conference, Ortho Clinical Diagnostics, U.S. Securities and Exchange Commission, HIV, Antibody, Risk, Industry, Press release, Hepatitis C, Acquisition, Failure, Growth, Laboratory, IVD, Hospital, LinkedIn, Privacy, Ortho, Blood, England, YouTube, Director, Risk management, Core

RARITAN, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (the “Company”), one of the world’s largest pure-play in vitro diagnostics (IVD) companies, today announced preliminary unaudited revenue results for the fourth quarter and fiscal year ended January 2, 2022. The Company is providing these updates in advance of its presentation at the J.P. Morgan Healthcare Conference on January 11, 2022.

Key Points: 
  • The Company expects to report its full fourth quarter and fiscal year 2021 financial results after the market close on Wednesday, February 16, 2022.
  • The preliminary financial results ranges described herein have not been audited and are subject to adjustment based on the Companys completion of year-end financial close processes.
  • Ortho Clinical Diagnostics will hold a conference call on Wednesday, February 16, 2022, at 5:00 pm ET to discuss the full financial results of the fourth quarter and fiscal year ended January 2, 2022.
  • Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) is one of the worlds largest pure-play in vitro diagnostics (IVD) companies dedicated to transforming patient care.

Quidel Announces Preliminary Revenue for Fourth Quarter 2021

Retrieved on: 
Thursday, January 6, 2022
Other Manufacturing, Research, Technology, Medical Devices, Infectious Diseases, Manufacturing, General Health, Health, Data Management, Science, COVID-19, Regulation of tobacco by the U.S. Food and Drug Administration, Infection, Topco, Information technology, Security (finance), History, NASDAQ, FDA, Investor relations, Mergers and acquisitions, City Code on Takeovers and Mergers, Corporation, Commission, Form, Webcast, Physician, Attention, Private Securities Litigation Reform Act, High Court, Compliance, Youth justice in England and Wales, Linear code, Nasdaq, Professional, Dangerous, Nature, Food, Prospectus, Company, Ownership, Patient, Conference, Transfusion medicine, Sale, Terminology, Securities Act of 1933, Acceleration, U.S. Securities and Exchange Commission, Public health, Tax, JOINT, Takeover, TO, Acquisition, Government, Failure, THE, Telephone, Delta, England, SVC, Emergency Use Authorization, Pharmaceutical industry, Cryptocurrency, Risk management, Quidel Corporation, Omicron, Ortho

The fourth quarter of 2021 put the final exclamation point on a truly outstanding and transformational year for Quidel, said Douglas Bryant, President and Chief Executive Officer of Quidel.

Key Points: 
  • The fourth quarter of 2021 put the final exclamation point on a truly outstanding and transformational year for Quidel, said Douglas Bryant, President and Chief Executive Officer of Quidel.
  • In the fourth quarter of 2021, we sold approximately 65 million QuickVue COVID-19 antigen tests and over 4 million Sofia SARS antigen tests the highest quarterly sales volume for tests for Quidel.
  • These preliminary results are based on managements initial analysis of operations for the quarter ended December 31, 2021.
  • Quidel expects to issue full financial results for the fourth quarter of 2021 and full year 2021 in February.

Halper Sadeh LLP Investigates FLOW, NEOG, CCMP, OCDX, HXOH; Shareholders are Encouraged to Contact the Firm

Retrieved on: 
Wednesday, January 5, 2022
Fraud, 3M, OTC, American Securities, Quidel Corporation, Lone Star Funds, CMC, NYSE, SPX, Hexion, NASDAQ, Advertising, Sale, Food safety, Security (finance), Entegris, Ortho

CMC Materials, Inc. (NASDAQ: CCMP)concerning potential violations ofthe federal securities laws and/or breaches of fiduciary duties relating to its sale to Entegris, Inc.

Key Points: 
  • CMC Materials, Inc. (NASDAQ: CCMP)concerning potential violations ofthe federal securities laws and/or breaches of fiduciary duties relating to its sale to Entegris, Inc.
  • Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options.
  • Halper Sadeh LLPrepresents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Halper Sadeh LLP Investigates OCDX, QDEL, FIBK, MNTV; Shareholders are Encouraged to Contact the Firm

Retrieved on: 
Tuesday, January 4, 2022
Advertising, Fraud, GLOBE, MNTV, NASDAQ, First Interstate, Interstate Highway System, Sale, Security (finance), Ortho, Momentive, Quidel Corporation, Zendesk

If you are an Ortho shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are an Ortho shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options.
  • Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Ortho Clinical Diagnostics to Participate in the 40th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 3, 2022
Twitter, COVID-19, IVD, Ortho, Blood, Facebook, Services and supports for people with disabilities, GLOBE, Interest, HIV, Food, Conference, YouTube, Hospital, Health, Antibody, Laboratory, Patient, Ortho Clinical Diagnostics, Nasdaq, Efficiency, LinkedIn, Hepatitis C, Food and Drug Administration, Medical device

RARITAN, N.J., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the worlds largest pure-play in vitro diagnostics (IVD) companies, today announced that members of its management team are scheduled to participate in the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, with a virtual presentation scheduled for 9:00am ET.

Key Points: 
  • RARITAN, N.J., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the worlds largest pure-play in vitro diagnostics (IVD) companies, today announced that members of its management team are scheduled to participate in the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, with a virtual presentation scheduled for 9:00am ET.
  • Interested parties can access a live webcast and replay of the presentation on the Investors page of the companys website at https://ir.orthoclinicaldiagnostics.com/ , under the Events section of the page.
  • Ortho Clinical Diagnostics (Nasdaq: OCDX) is one of the worlds largest pure-play in vitro diagnostics (IVD) companies dedicated to transforming patient care.
  • Ortho's customized solutions enhance clinical outcomes, improve efficiency, overcome lab staffing challenges and reduce costs.